Retinal vascular diseases(RVD)are among the leading causes of blindness worldwide, with their prevalence showing an increasing trend year by year. Among them, age-related macular degeneration(ARMD), diabetic macular edema(DME), and retinal vein occlusion(RVO)are the most common types. Faricimab, developed by Roche's CrossMAB platform, is a novel bispecific monoclonal antibody that can simultaneously target and inhibit vascular endothelial growth factor-a(VEGF-A)and angiopoietin-2(Ang-2). The dual inhibition of these two key factors by Faricimab endows it with the potential to regulate angiogenesis and inflammatory responses more comprehensively and effectively, thus bringing new opportunities for the treatment of RVD.